ÂÜÀòÂÒÂ×

Kevin Skol has nearly 20 years of experience in the pharmaceutical industry, primarily in corporate development, alliance management, strategy, and licensing roles. He previously worked at RNA target-based companies Ionis Pharmaceuticals and Digital Gene Technologies and at specialty pharmaceutical companies Elan Corporation and Valeant Pharmaceuticals. At Ionis he led business development and licensing efforts that resulted in major pharmaceutical partnerships with Astra Zeneca, Roche, Janssen, Novartis, and Biogen. The combined transaction value of collaborative agreements and partnerships which he led throughout his career is estimated at over $2 billion.

Mr. Skol graduated with a B.A. from Yale University and has an MBA from Harvard Business School.